Microba Life Sciences Limited | May 26, 2022
Microba Life Sciences Limited has signed a strategic partnership agreement with nib Holdings Limited backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.
Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based on their microbiome test results, leveraging the recommendations from Microba’s Analysis Platform.
This personalised, pharmacy-integrated service model – delivered with trained, registered pharmacists – will bring a level of science and personalisation to an industry which commonly provides customers with one-size-fits-all solutions.
Midnight Health CEO, Nic Blair said: “We are experiencing strong demand for innovative online healthcare solutions aligned to an individual needs. We already have more than 13,000 subscribers across our existing brands with strong month-on-month growth. Many of our customers are looking for gut health solutions and we are proud to bring the Vidality product to our customers in partnership with Microba”.
The Agreement was signed, for an initial period of 3 years, after a successful pilot which tested the service model and product offering. It further demonstrates Microba’s scalable technology and ability to deliver evidence-based gut health solutions together with distribution partners.
“Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology”.
Microba CEO, Dr Luke Reid
This delivers on an undertaking in the Company’s Prospectus to enter into an Australian partnership with a fast growth innovative consumer healthcare company.
This announcement has been authorised for release by the Board.
About Midnight Health
Midnight Health delivers innovative online healthcare solutions through a patient-led digital platform. With the primary goal of democratising healthcare and enabling individuals to take control of their own healthcare, Midnight Health integrate telehealth technology, doctors, pharmacy network and other partners to provide a seamless patient experience for fast, convenient and discreet access to treatments, prescriptions and education through niche digital brand platforms.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
Avania | June 21, 2022
Avania, the preeminent, full-service global MedTech contract research organization announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital current investor who intends to retain a minority stake will actively support management’s plans to advance Avania’s development as a MedTech solution provider.
Headquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology.
Astorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania’s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions.
“The platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader. The largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.”
Sapna Hornyak, president and CEO of Avania
“We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,” said Managing Partner of Astorg Mid-Cap Edouard Pillot. “Being one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg’s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg’s broader healthcare portfolio.”
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
Astorg is a leading private equity firm with over €17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg.
About Kester Capital
Kester Capital is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.
Forescout Technologies | February 02, 2022
Forescout Technologies, the leader in Active Defense for the Enterprise of Things, today announced its acquisition of CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks. The acquisition further strengthens Forescout’s position as the industry leader in out-of-the-box support for the broadest set of connected device types across IT, IoT, OT and IoMT devices.
“Forescout is seeing rapid growth in healthcare, a market the company has always focused attention on from a technology and sales perspective. Cybersecurity for IoMT, much like cybersecurity for OT devices, requires specific expertise and technologies. We are pleased to have the CyberMDX team join Forescout as we continue delivering new capabilities on our market-leading platform and grow our R&D center.”
Wael Mohamed, Chief Executive Officer of Forescout
Forescout is recognized by many of the world’s largest organizations as the leader in device visibility and control, ensuring customers can see all the devices connected to their networks, continuously and in real-time, and then take automated action to mitigate risks. CyberMDX offers a leading solution for visibility and risk management of IoMT devices. Together, Forescout and CyberMDX have a powerful platform that delivers an easy-to-use, scalable and agentless approach to device visibility, classification, threat detection and incident response focused on IoMT devices to better serve healthcare organizations.
“CyberMDX enables hospitals to provide quality care by securing and protecting the systems and devices they rely on every day to treat patients and save lives,” said Amir Magner, President and Co-Founder of CyberMDX. “We are thrilled to join the Forescout team where our innovation can continue to make a profound difference to healthcare organizations around the world.”
Broad coverage across all device types is essential as larger organizations, such as healthcare, almost always have a wide variety of device types, including IT and a rapidly expanding number of IoT devices, in addition to IoMT and OT devices. In 2018, Forescout acquired Security Matters, a leading providing of solutions for visibility and risk management for OT systems, which are also known as industrial control systems (ICS). Forescout has the largest number of deployments of OT infrastructure protection solutions globally, with major deployments in critical infrastructure sectors such as energy and utilities. Forrester recently recognized Forescout in its inaugural Industrial Control Systems (ICS) Security Solutions Wave, 2021 as the top vendor for market presence for product revenue, total number of customers and deal size. CyberMDX, which was recognized as a Medical Device Security Solution Leader in The Forrester New Wave™: Connected Medical Device Security, Q2 2020, further demonstrates Forescout’s commitment to providing organizations with the most comprehensive solution across all device types.
Recently, Forescout announced that its platform discovered 66% more devices than originally expected at the University Health Network (UHN), a group of four hospitals in Toronto, Canada that includes The Toronto General Hospital, which Newsweek ranked in 2021 as the 4thbest hospital in the world. Among many benefits, UHN is leveraging the Forescout platform to “deal with the exponential increase in the number of IoT devices and ever-increasing volume of sophisticated threats, including ransomware,” according to Kashif Parvaiz, Chief Information Security Officer, at UHN. With the addition of CyberMDX’s solution, Forescout customers will be able to gain deeper visibility and risk management of their IoMT and medical devices.
Over the past 20 years, Forescout has built unique strength in device intelligence and network fabric technology for device discovery and classification. The company’s Device Cloud database contains over 15 million device fingerprints and ensures Forescout's customers automatically receive highly specific, out-of-the-box device classification capabilities from the Forescout platform for millions of different types of devices.
Forescout Technologies, Inc. actively defends the Enterprise of Things by identifying, segmenting and enforcing compliance of every connected thing. Fortune 1000 companies trust Forescout as it provides one of the most widely deployed, enterprise-class platforms at scale across IT, IoT, OT and IoMT managed and unmanaged devices. Forescout arms customers with extensive device intelligence, data and policies to allow organizations across every industry to accurately classify risk, detect anomalies and quickly remediate cyberthreats without disruption of critical business assets. Don’t just see it. Secure it.
FUTURE OF HEALTHCARE
Winner Medical | June 02, 2022
Winner Medical Co. Ltd. a leading manufacturer of disposable wound care and surgical products, announced on May 18 that it will acquire a majority 65.55% stake in Hunan Pingan Medical Device Technology Co. Ltd. for 652 million yuan as the Company continues to expand its disposable medical supply lineup.
Upon the completion of the deal, Winner Medical is set to hold a total of 68.7% stake in Pingan Medical for a total of 752 million yuan.
The Company's move comes as it looks to make a foray into the field of injection products to diversify its product offerings besides consumer products, and comes in line with its strategy to provide one-stop disposable medical supply solutions.
Established in 2010, Pingan Medical mainly produces disposable medical devices, such as syringes, infusion sets, and blood collection tubes among other medical supplies. In 2021, Pingan Medical recorded 360 million yuan in revenue and booked a net profit of 85 million yuan.
The acquisition will leverage both companies' strengths and help fill the product gap in injection-related disposables of Winner Medical, enabling it to expand into new medical verticals and achieve its goal of becoming a major supplier for the domestic market.
Specifically, the Company plans to roll out medical sets that comprise needle-type products from Pingan Medical and wound care supplies from Winner Medical, providing one-stop customized solutions for hospitals and large medical centers.
Meanwhile, Winner Medical will help Pingan Medical with its industry-leading R&D capabilities to develop medical device solutions and build smart manufacturing plants.
To fuel the growth based on the new deal, Winner Medical has signed an investment note with the local government of Li County in Hunan Province, where Pingan Medical is headquartered, to build medical equipment production lines, smart warehousing, and R&D facilities.
The latest deal follows Winner Medical's April-11 acquisition of wound dressing maker Zhejiang Longterm Medical Technology Co. Ltd. as part of its expansion strategy to stay competitive in the area of high-end wound dressings. The Company has also set up a dedicated team to promote its self-developed wound dressing products as the market for such medical supplies is still in its infancy in China.
Founded in 1991, Winner Medical has made efforts to offer quality cotton-based medical dressings and disposables, and will continue to push ahead with its strategy to diversify its product lineup and boost consumption. On the manufacturing front, the Company aims to expand to new medical verticals through acquisitions, while on the consumption front, it plans to enhance product sales through digitization and gradually phasing out less popular products.
As such, the Company has made significant progress in digitizing its operations. Winner Medical has gone live on multiple e-commerce platforms, and has gone digital in terms of online and offline warehousing and order management.